Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Multiple Sclerosis

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 18 articles:
HTML format
Text format



Single Articles


    June 2017
  1. XIA Z, Friedlander RM
    Minocycline in Multiple Sclerosis - Compelling Results but Too Early to Tell.
    N Engl J Med. 2017;376:2191-2193.
    PubMed     Text format    


  2. METZ LM, Li DKB, Traboulsee AL, Duquette P, et al
    Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis.
    N Engl J Med. 2017;376:2122-2133.
    PubMed     Text format     Abstract available


    April 2017
  3. DEISENHAMMER F, Auer M, Hegen H
    Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
    N Engl J Med. 2017;376:1693-4.
    PubMed     Text format    


  4. MILDINER S, Malnick S
    Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
    N Engl J Med. 2017;376:1692-3.
    PubMed     Text format    


  5. SHARP MK
    Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
    N Engl J Med. 2017;376:1692.
    PubMed     Text format    


  6. KORN T, Oukka M
    A BAFFling Association between Malaria Resistance and the Risk of Multiple Sclerosis.
    N Engl J Med. 2017;376:1680-1681.
    PubMed     Text format    


  7. MONTALBAN X, Belachew S, Wolinsky JS
    Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
    N Engl J Med. 2017;376:1694.
    PubMed     Text format    


  8. SCHOERGENHOFER C, Jilma B
    Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
    N Engl J Med. 2017;376:1693.
    PubMed     Text format    


  9. HAUSER SL, Belachew Sh, Kappos L
    Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
    N Engl J Med. 2017;376:1694.
    PubMed     Text format    


  10. STERI M, Orru V, Idda ML, Pitzalis M, et al
    Overexpression of the Cytokine BAFF and Autoimmunity Risk.
    N Engl J Med. 2017;376:1615-1626.
    PubMed     Text format     Abstract available


    December 2016
  11. MONTALBAN X, Hauser SL, Kappos L, Arnold DL, et al
    Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
    N Engl J Med. 2016 Dec 21. doi: 10.1056/NEJMoa1606468.
    PubMed     Text format     Abstract available


  12. HAUSER SL, Bar-Or A, Comi G, Giovannoni G, et al
    Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    N Engl J Med. 2016 Dec 21. doi: 10.1056/NEJMoa1601277.
    PubMed     Text format     Abstract available


  13. CALABRESI PA
    B-Cell Depletion - A Frontier in Monoclonal Antibodies for Multiple Sclerosis.
    N Engl J Med. 2016 Dec 21. doi: 10.1056/NEJMe1614717.
    PubMed     Text format    


    August 2016
  14. WEISFELD-ADAMS JD
    The Abyss.
    N Engl J Med. 2016;375:713-5.
    PubMed     Text format    


    April 2016
  15. PROBSTEL AK, Kuhle J, Lecourt AC, Vock I, et al
    Multiple Sclerosis and Antibodies against KIR4.1.
    N Engl J Med. 2016;374:1496-8.
    PubMed     Text format    


  16. CHASTRE A, Hafler DA, O'Connor KC
    Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis.
    N Engl J Med. 2016;374:1495-6.
    PubMed     Text format    


    November 2015
  17. MURRAY SG, Wachter RM, Cho KC, Dhaliwal G, et al
    CLINICAL PROBLEM-SOLVING. A Breakthrough Diagnosis.
    N Engl J Med. 2015;373:1865-70.
    PubMed     Text format    


    October 2015
  18. KAPPOS L, Wiendl H, Selmaj K, Arnold DL, et al
    Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    N Engl J Med. 2015;373:1418-28.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: